ATE243514T1 - Verwendung von darifenacin zur verbesserung der wahrnehmung - Google Patents
Verwendung von darifenacin zur verbesserung der wahrnehmungInfo
- Publication number
- ATE243514T1 ATE243514T1 AT97303879T AT97303879T ATE243514T1 AT E243514 T1 ATE243514 T1 AT E243514T1 AT 97303879 T AT97303879 T AT 97303879T AT 97303879 T AT97303879 T AT 97303879T AT E243514 T1 ATE243514 T1 AT E243514T1
- Authority
- AT
- Austria
- Prior art keywords
- darifenacin
- improve perception
- treatment
- pharmaceutically acceptable
- cognitive impairment
- Prior art date
Links
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 title abstract 3
- 229960002677 darifenacin Drugs 0.000 title abstract 3
- 230000008447 perception Effects 0.000 title 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01007—Acetylcholinesterase (3.1.1.7)
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Control Of Eletrric Generators (AREA)
- Soil Working Implements (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Chemical Treatment Of Metals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9612710.5A GB9612710D0 (en) | 1996-06-18 | 1996-06-18 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE243514T1 true ATE243514T1 (de) | 2003-07-15 |
Family
ID=10795468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97303879T ATE243514T1 (de) | 1996-06-18 | 1997-06-05 | Verwendung von darifenacin zur verbesserung der wahrnehmung |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5837724A (de) |
| EP (1) | EP0813870B1 (de) |
| JP (1) | JP3453493B2 (de) |
| KR (1) | KR980000445A (de) |
| AT (1) | ATE243514T1 (de) |
| AU (1) | AU2495697A (de) |
| CA (1) | CA2208111C (de) |
| DE (1) | DE69722999T2 (de) |
| DK (1) | DK0813870T3 (de) |
| ES (1) | ES2197972T3 (de) |
| GB (1) | GB9612710D0 (de) |
| HU (1) | HUP9701060A3 (de) |
| IL (1) | IL121036A0 (de) |
| PT (1) | PT813870E (de) |
| ZA (1) | ZA975311B (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19707655A1 (de) * | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
| US20040209849A1 (en) * | 1998-11-27 | 2004-10-21 | Sanochemia Pharmazeutika Aktiengesellschaft | Use of effectors of the central cholinergic nervous system for treatment of delirium |
| GB0207104D0 (en) * | 2002-03-26 | 2002-05-08 | Pfizer Ltd | Stable hydrate of a muscarinic receptor antagonist |
| WO2004089892A2 (en) * | 2003-04-01 | 2004-10-21 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity |
| EP4088717A1 (de) | 2008-03-27 | 2022-11-16 | Chase Pharmaceuticals Corporation | Kombination aus einem nspacha (peripheres anticholinergikum) wie solifenacin und einem achei (acetylcholinesteraseinhibitor) wie donepezil zur behandlung von demenz |
| EP3061821B1 (de) * | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Zusammensetzungen zur behandlung von durch muscarinrezeptoraktivierung gelinderten leiden |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| SG11201909595VA (en) * | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| IL281809B (en) | 2018-09-28 | 2022-09-01 | Karuna Therapeutics Inc | Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5233053A (en) * | 1989-03-17 | 1993-08-03 | Pfizer Inc. | Pyrrolidine derivatives |
| GB9400600D0 (en) * | 1994-01-14 | 1994-03-09 | Pfizer Ltd | Treatment of motion seckness |
-
1996
- 1996-06-18 GB GBGB9612710.5A patent/GB9612710D0/en active Pending
-
1997
- 1997-06-05 DE DE69722999T patent/DE69722999T2/de not_active Expired - Lifetime
- 1997-06-05 DK DK97303879T patent/DK0813870T3/da active
- 1997-06-05 AT AT97303879T patent/ATE243514T1/de active
- 1997-06-05 EP EP97303879A patent/EP0813870B1/de not_active Expired - Lifetime
- 1997-06-05 ES ES97303879T patent/ES2197972T3/es not_active Expired - Lifetime
- 1997-06-05 PT PT97303879T patent/PT813870E/pt unknown
- 1997-06-09 IL IL12103697A patent/IL121036A0/xx unknown
- 1997-06-10 JP JP15189997A patent/JP3453493B2/ja not_active Expired - Lifetime
- 1997-06-11 US US08/872,891 patent/US5837724A/en not_active Expired - Lifetime
- 1997-06-16 CA CA002208111A patent/CA2208111C/en not_active Expired - Lifetime
- 1997-06-17 ZA ZA975311A patent/ZA975311B/xx unknown
- 1997-06-17 KR KR1019970025073A patent/KR980000445A/ko not_active Ceased
- 1997-06-17 HU HU9701060A patent/HUP9701060A3/hu unknown
- 1997-06-17 AU AU24956/97A patent/AU2495697A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT813870E (pt) | 2003-10-31 |
| JPH1059848A (ja) | 1998-03-03 |
| ES2197972T3 (es) | 2004-01-16 |
| DK0813870T3 (da) | 2003-08-18 |
| HUP9701060A2 (hu) | 1998-12-28 |
| DE69722999T2 (de) | 2003-12-18 |
| JP3453493B2 (ja) | 2003-10-06 |
| IL121036A0 (en) | 1997-11-20 |
| CA2208111C (en) | 2002-10-15 |
| ZA975311B (en) | 1998-12-17 |
| GB9612710D0 (en) | 1996-08-21 |
| CA2208111A1 (en) | 1997-12-18 |
| KR980000445A (ko) | 1998-03-30 |
| DE69722999D1 (de) | 2003-07-31 |
| HU9701060D0 (en) | 1997-08-28 |
| HUP9701060A3 (en) | 1999-03-29 |
| AU2495697A (en) | 1998-01-08 |
| EP0813870B1 (de) | 2003-06-25 |
| EP0813870A1 (de) | 1997-12-29 |
| US5837724A (en) | 1998-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69729646D1 (de) | Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv | |
| DE69733329D1 (de) | Verwendung von Taurin zur Behandlung oder Vorbeugung von ischämischen Verletzungen | |
| DE69712003D1 (de) | Modifikation von xylanase zur Verbesserung von Thermophilicität, alkophilicität und thermostabilität | |
| DE69603734D1 (de) | Blockcopolymere von Polyolefinen mit Polyurethanen, Copolyestern oder Copolyamiden und ihre Verwendung | |
| DE69728771T2 (de) | Herzschrittmacher mit treppensteigunterscheidung | |
| DE69941566D1 (de) | N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie | |
| ATE271393T1 (de) | Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern | |
| EA199800667A1 (ru) | Новые фенантридины | |
| DE69838338D1 (de) | Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen | |
| DE69821667D1 (de) | Kardioverter zur Behandlung von Vorhofflattern | |
| PT936908E (pt) | Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela) | |
| DE69838728D1 (de) | Methoden und zusammensetzungen zum wirksameren abfangen von sauerstoff | |
| DE69526935D1 (de) | Verwendung von mycobacterium zur tumorbehandlung | |
| DE69515070D1 (de) | Zusammensetzung auf der Basis von alpha-Pyronen zur Induzierung und Stimulierung des Haarwachstums und/oder zur Verlangsamung des Haarausfalls und ihre Verwendung | |
| DE69712578D1 (de) | Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase | |
| DE69714736D1 (de) | Polyaminen mit erhöhten nutzen für das aussehen von gewebe | |
| DE69306915D1 (de) | Kombination zur Detektion von Weichgewebeanomalien | |
| DE69722999D1 (de) | Verwendung von Darifenacin zur Verbesserung der Wahrnehmung | |
| DE69729768D1 (de) | Herzschrittmacher mit Bestimmung des anaeroben Schwellwertes | |
| DE69626816D1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
| DE59710757D1 (de) | Verwendung von mikroporösem polyolefin zur absorption von schweiss und anderen körperausdünstungen | |
| DE69518438D1 (de) | Behandlung von übereregten nervenzellenfunktionen | |
| DE69709579D1 (de) | System zur Überwachung von Biozidbehandlungen | |
| DE59711240D1 (de) | Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge | |
| DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0813870 Country of ref document: EP |